Clinical Trial Update: The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

View source ↗

Summary

This completed FAACET study evaluated Fabrazyme in combination with ARB/ACE inhibitor therapy in Fabry disease patients with proteinuria. The update indicates t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Fabry Disease, Proteinuria | Status: COMPLETED